AnHeart Therapeutics

Acquired

Clinical-stage biopharmaceutical company developing precision oncology therapeutics, including taletrectinib for ROS1 fusion-positive NSCLC. Acquired by Nuvation Bio in 2024.

AnHeart Therapeutics is a biotech company in New York, China, founded in 2018. It has raised $75.6M across 3 rounds, most recently a $61.0M Series B in December 2021.

Headquarters
New York
Employees
51–200
Founded
2018
Business Model
B2B
Total Funding
$75.6M
Last Round
$61.0M Series BDec 2021
Rounds
3
Acquired by
Nuvation Bio Inc.Mar 2024

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 3 funding rounds and 5 investors for this company. to use credits for reveals, or explore the API.

About

AnHeart Therapeutics is a clinical-stage global biopharmaceutical company founded in 2018 and headquartered in New York City, with significant operations in China. The company focused on developing precision oncology therapeutics, most notably taletrectinib, a next-generation ROS1/NTRK inhibitor targeting ROS1 fusion-positive non-small cell lung cancer (NSCLC) and other solid tumors. AnHeart built a broad pipeline addressing underserved cancer subtypes and was acquired by Nuvation Bio in April 2024 in an all-stock transaction, transforming Nuvation into a late-stage global oncology company with commercial-stage potential.

Funding & Exit History

Data from Indexed.vcUpdated
AcquisitionMar 2024

3 more funding events

  • Series B20215 investors
  • Series A20201 investor
  • Series A20191 investor

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Companies in related industries

BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech
Corporate RoundTotal funding$2.8BJan 2020
Avenzo

Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...

San Diego, United States1–10Biotech
Series BTotal funding$832.0MSep 2025
Bicycle TherapeuticsIPO

Novel bicyclic peptides and drug conjugates for cancer

Cambridge, United States201–500Biotech
Private EquityTotal funding$607.0MJan 2024
Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech
Private EquityTotal funding$3.0BJan 2004

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

AnHeart Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/anheart-therapeutics"><img src="https://indexed.vc/api/badge/company/anheart-therapeutics" alt="AnHeart Therapeutics on Indexed.vc" width="260" height="76" /></a>